MDCK-MRP2 - Dkfz

258
Forschungsschwerpunkt D
Tumorimmunologie
für eine aktive Tumorvakzinierung dar, da die im Wirt gereiften
und somit gegenüber dem Wirt toleranten T-Zellen
Tumorantigene weiterhin als fremd erkennen; iv. Es muss
erwähnt werden, dass wir bei allen bisherigen Vakzinierungsprotokollen
entweder mit Tumoreskapemechanismen oder
Gegenattacken durch den Tumor konfrontiert wurden.
Wenngleich Tumoreskape bzw. Gegenattacken durch den
Tumor den Therapieeffekt nicht aufgehoben haben, könnte
die Erfolgs- / Heilungsquote bei Überwindung dieser Hindernisse
deutlich gesteigert werden. Wir werden entsprechende
Überlegungen in unsere weiterführenden Untersuchungen
einschließen.
Publikationen (* = externer Koautor)
[1] Marhaba M and Zöller M. CD44 in cancer progression: Adhesion,
migration and growth regulation. Histochemical J, 35:211-
231, 2004.
[2] Engel P. Liganden und Funktion von CD44v10 und CD44v3
beim Lymphozytentraffik. Fachbereich Biologie, Universität
Oldenburg, 2002.
[3] Zöller M, McElwee KJ*, Engel P, Hoffmann R*. Transient CD44
variant isoform expression and reduction in CD4+/CD25+ regulatory
T cells in C3H/HeJ mice with alopecia areata. J Invest
Dermatol, 118: 983-992, 2002.
[4] McElwee KJ*, Freyschmidt-Paul P*, Zöller M, Hoffmann R*.
Alopecia areata susceptibility in rodent models. J Investig
Dermatol Symp Proc, 8: 182-7, 2003.
[5] Zöller M, Freyschmidt-Paul P*, Vitacolonna M, McElwee KJ*,
Hummel S, Hoffmann R. Chronic delayed type hypersensitivity
reaction as a means to cure alopecia areata. Clin Exp Immunol,
135: 398-408, 2004
[6] Zöller M, McElwee KJ*, Vitacolonna M, Hoffmann R*. The progressive
state of alopecia areata and therapeutic response towards
a contact sensitizer are reflected in peripheral blood
mononuclear cells, Exp Derm, in press
[7] Christ O, Schmidt DS, Günthert U*, Zöller M. The CD44v6
isoform supports stem cell and lymphoid progenitor maturation. J
Leukoc Biol, 71: 33-46, 2002.
[8] Marhaba R, Bourouba M, Zöller M. CD44v7 interferes with
activation-induced cell death by up-regulation of anti-apoptotic
gene expression. J Leukoc Biol, 74: 135-148, 2003.
[9] Freyschmidt-Paul P*, McElwee KJ*, Zöller M, Hoffmann R*.
Interleukin-10 deficient mice are less susceptible to the induction
of alopecia areata. J Invest Dermatol, 119: 980-982, 2002.
[10] McElwee KJ*, Hoffmann R*, Zöller M. Resistance to alopecia
areata in C3H/HeJ mice is associated with increased expression
of regulatory cytokines and a failure to recruit CD4 + and CD8 +
cells. J Invest Dermatol, 119: 1426-1433, 2002.
[11] Zöller M, McElwee KJ*, Vitacolonna M, Hoffmann R*.
Apoptosis resistance in peripheral blood lymphocytes of alopecia
areata patients, J Leukoc Biol, in revision
[12] Schmidt DS. Membranmikrodomänen und CD44v6Fakultät für
Bio- und Geowissenschaften, Universität Karlsruhe, 2002.
[13] Yang XW*, Claas C, Kraeft SK*, et al. Palmitoylation of
tetraspanin proteins: Modulation of CD151 lateral interactions,
subcellular distribution, and integrin-dependent cell morphology
Mol Biol Cell 13: 767-781, 2002.
[14] Schmidt DS, Schnölzer M, Klingbeil P, Zöller M. CD44 variant
isoforms associate with tetraspanins and selectively with EpCAM:
consequences on cell cell and cell matrix adhesion. Exp Cell Res.,
2004 (E pub ahead of print)
[15] Herlevsen M, Schmidt DS, Miyazaki K*, Zöller M.The association
of the tetraspanin D6.1A with the alpha6beta4 integrin supports
cell motility and liver metastasis formation. J Cell Sci, 116:
4373-4390, 2003.
[16] Amtmann E, Baader W, Zöller M. Neutral sphingomyelinase
inhibitor C11AG prevents lipopolysaccharide-induced macrophage
activation. Drugs Exp Clin Res, 29: 5-13, 2003.
Abteilung D060
Tumorprogression und Tumorabwehr
[17] Amtmann E, Zöller M. Stimulation of CD95 induced apoptosis
in T-cells by a subtype specific neutral sphingomyelinase inhibitor.
Biochemical Pharmacology, in press
[18] Friebolin W, Schilling G, Zöller M, Amtmann E. Synthesis and
structure-activity relationship in vitro of novel antitumoral platinum
xanthate complexes. J Med Chem,47: 2256-2263, 2004
[19] Millet R*, Urig S*, Gromer S*, Lemaire A*, Amtmann E,
Moulinoux JP*, Schirmer H*, Becker K*, Davioud-Charvet E*.
Synthesis of 5-Nitro-2-furancarbohydrazides and their cis-
DiamminedichloroPlatinum Complexes as Irreversible Inhibitors of
Human Thioredoxin Reductase. J Med Chem, in revision
[20] Zöller M. Immunotherapy of cancer by active vaccination:
does allogeneic bone marrow transplantation after nonmyeloablative
conditioning provide a new option? Technol Cancer
Res Treat, 2: 237-260, 2003.
[21] Zöller M, Matzku S. Active vaccination after allogeneic bone
marrow cell transplantation: a new option in the immunotherapy
of cancer? Arch Immun Ther Exper, 50: 197-224, 2002.
[22] Zöller M. Immunotherapy of Cancer: Allogeneic bone marrow
transplantation after non-myeloablative conditioning as a
new option for the elderly patient. Cancer Immunol Immunother,
2004 (E pub ahead of print)
[23] Zöller M. Tolerance induction by tumor vaccination, J
Immunother, 25: 162-175, 2002.
[24] Hummel S, Wilms D, Vitacolonna M, Zöller M. Improved
therapeutic efficacy of allogeneic bone marrow cell reconstitution
in the non-myeloablatively conditioned tumor bearing host by donor
T cell and host NK depletion. J Leukoc Biol, 72: 898-912,
2002.
[25] Zöller M. Tumor vaccination after allogeneic bone marrow
cell reconstitution of the non-myeloablatively conditioned tumorbearing
host, J Immunol, 171: 6941-6953, 2003.
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003